8-K - VYNE Therapeutics Inc. | StockGist

Current Report Details

Event Type

Management Change+5 More

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

of this Current Report on Form 8-K is incorporated herein by reference. Item 7.01 Regulation FD Disclosure. On December 17, 2025, the Company and Yarrow issued

Material Agreement

Source Document

3.02

Unregistered Sales of Equity Securities. To the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorp

Securities Issuance

5.01

Changes in Control of Registrant. To the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorporated

Corporate Governance

5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. To the extent

Management Change

7.01

, including Exhibits 99.1, and 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (

Regulation Fd

9.01

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 2.1 Agreement and Plan of Merger and Reorganization, dated December 17, 2025, by and

Exhibits Only

Source Document

Exhibits (9)

10.1

EXHIBIT 10.1

10.2

EXHIBIT 10.2

10.3

EXHIBIT 10.3

10.4

EXHIBIT 10.4

10.5

EXHIBIT 10.5

2.1

EXHIBIT 2.1

8-K

FORM 8-K

99.1

EXHIBIT 99.1

99.2

EXHIBIT 99.2